SCONE™ Study Is Actively Recruiting At Multiple Sites Around The World
The purpose is to study the effectiveness and safety of SCONE™ neuromodulation therapy for individuals with neurogenic lower urinary tract dysfunction due to Stroke, Spinal Cord Injury, or Multiple Sclerosis.
You can find a list of clinical trial sites below, and full details about the inclusion and exclusion criteria HERE
At SpineX, we are committed to improving the lives of people living with neurogenic bladder.
If you are interested in learning more about the SCONE™ clinical trial, please Email us: info@spinex.co
You can find a list of clinical trial sites below, and full details about the inclusion and exclusion criteria HERE
Why Is SCONE™ Unique?
- World’s first non-invasive Spinal Neuromodulator
- Delivers novel proprietary waveforms
- Activates the neurons in the Spinal Cord
- Capable of retraining the Brain and the Spinal Cord
Current electrical stimulation treatments for bladder dysfunctions are highly invasive and often ineffective to treat neurogenic bladders.